A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants

Exclusion Criteria

• •Known or suspected hypersensitivity to study interventions or related products.
• •Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method.
• •Exposure to an investigational medicinal product within 30 days or 5 half-lives of the investigational medicinal product (if known), whichever is longer, before screening.
• •Participant is unable to refrain from or anticipates the use of any drug known to be a moderate or strong inhibitor or inducer of uridine 5'-diphospho-glucuronosyltransferase (UGT) enzymes, CYP3A4, CYP2C9, MATE1, OATP1B1/1B3, BCRP, OCT2, or P-gp, including St. John's Wort for 28 days prior to dosing and throughout the study.
• •Use of any medication with unknown or unspecified content within 90 days before screening.
• •Use of or intent to use prescription medicinal products or non-prescription drugs (including vitamins and herbal supplements) within 14 days prior to dosing and throughout the study, as declared by the participant, except for:
• •Adequate contraceptive methods.
• •Hormone replacement therapy (HRT) (for menopausal females).
• •Over-the-counter topical medications known to not reach systemic circulation.
• •Occasional use of acetaminophen up to 2 grams (g) (4 x 0.5 g) daily.
• •Not able or not willing to adhere to study procedures, including:
• •Eating the food provided in the study.
• •Refraining from ingesting food or drinks that are not allowed during the study.
• •Swallowing tablets.
• •Abstaining from concomitant medication not allowed during the study.